Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy
暂无分享,去创建一个
P. Kang | W. Frishman | R. Eberhardt | R. M. Kevak | Robert T. Eberhardt | Rudolph M. Kevak | Peter M. Kang | William H. Frishman | Rudolph M. Kevak
[1] K. Kubo,et al. Non-peptide Angiotensin II Receptor Antagonists , 1995 .
[2] T. Baussant,et al. Angiotensin‐Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans , 1993, Journal of cardiovascular pharmacology.
[3] P. Timmermans,et al. Angiotensin II receptors and functional correlates. , 1992, American journal of hypertension.
[4] M. Weber,et al. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. , 1992, American journal of hypertension.
[5] F. Suzuki,et al. [Renin-angiotensin system]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.
[6] R. Alexander,et al. Molecular cloning of AT1 angiotensin receptors. , 1992, American journal of hypertension.
[7] L. Hansson,et al. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. , 1992, American journal of hypertension.
[8] P. Timmermans,et al. Rationale for the chemical development of angiotensin II receptor antagonists. , 1992, American journal of hypertension.
[9] Y. Christen,et al. Clinical experience with angiotensin II receptor antagonists. , 1992, American journal of hypertension.
[10] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[11] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[12] T. Meyer,et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. , 1992, The Journal of clinical investigation.
[13] P. Timmermans,et al. Effect of Blocking Angiotensin II Receptor Subtype on Rat Sympathetic Nerve Function , 1992, Hypertension.
[14] R D Smith,et al. Angiotensin II receptor subtypes. , 1992, American journal of hypertension.
[15] V. Lotti,et al. Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart. , 1992, The Journal of pharmacology and experimental therapeutics.
[16] B. Kobilka,et al. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. , 1992, Biochemical and biophysical research communications.
[17] Y. Christen,et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist , 1992, Clinical pharmacology and therapeutics.
[18] C. Alpers,et al. Renal injury from angiotensin II-mediated hypertension. , 1992, Hypertension.
[19] N. Aiyar,et al. Cloning and characterization of a human angiotensin II type 1 receptor. , 1992, Biochemical and biophysical research communications.
[20] L. Musgrove,et al. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. , 1992, Biochemical and biophysical research communications.
[21] E. Jackson,et al. Effects of Angiotensin Subtype 1 and Subtype 2 Receptor Antagonists in Normotensive Versus Hypertensive Rats , 1991, Hypertension.
[22] F. M. Bumpus,et al. Angiotensin I and II Some Early Observations Made at The Cleveland Clinic Foundation and Recent Discoveries Relative to Angiotensin II Formation in Human Heart , 1991, Hypertension.
[23] P. Timmermans,et al. Angiotensin II Receptor Antagonists From Discovery to Antihypertensive Drugs , 1991, Hypertension.
[24] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. , 1991, European journal of pharmacology.
[25] J. Wood,et al. Prolonged Angiotensin II Antagonism in Spontaneously Hypertensive Rats: Hemodynamic and Biochemical Consequences , 1991, Hypertension.
[26] K. Catt,et al. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. , 1991, Molecular pharmacology.
[27] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[28] P. Timmermans,et al. Effect of Angiotensin II Antagonism on Canine Renal Sympathetic Nerve Function , 1991, Hypertension.
[29] S. Gardiner,et al. Cardiac haemodynamic effects of the non‐peptide, angiotensin II‐receptor antagonist, DuP 753, in conscious Long Evans and Brattleboro rats , 1991, British journal of pharmacology.
[30] R. Alexander,et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor , 1991, Nature.
[31] J. Murray,et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor , 1991, Nature.
[32] P. Timmermans,et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. , 1991, Hypertension.
[33] P. Timmermans,et al. Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist. , 1991, European journal of pharmacology.
[34] P. Timmermans,et al. In vitro pharmacology of DuP 753. , 1991, American journal of hypertension.
[35] J. Laragh,et al. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. , 1991, American journal of hypertension.
[36] P. Timmermans,et al. Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. , 1991, American journal of hypertension.
[37] P. Timmermans,et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. , 1991, American journal of hypertension.
[38] Y. Christen,et al. Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II , 1991, Circulation.
[39] F. Nantel,et al. DuP 753 Is a Specific Antagonist for the Angiotensin Receptor , 1991, Hypertension.
[40] P. Timmermans,et al. DuP 753 is a potent nonpeptide antagonist of angiotensin II receptors in isolated perfused rat kidney and cultured renal cells. , 1991, American journal of hypertension.
[41] Y. Christen,et al. Dose-response relationships following oral administration of DuP 753 to normal humans. , 1991, American journal of hypertension.
[42] P. Timmermans,et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. , 1991, American journal of hypertension.
[43] P. Timmermans,et al. Effects of DuP 753 on proximal nephron and renal transport. , 1991, American journal of hypertension.
[44] L. Pease,et al. Angiotensin II receptor heterogeneity. , 1991, American journal of hypertension.
[45] J. Laragh,et al. Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats. , 1991, American journal of hypertension.
[46] J. Wood,et al. Involvement of the Renin–Angiotensin System in Ischemic Damage and Reperfusion Arrhythmias in the Isolated Perfused Rat Heart , 1991, Journal of cardiovascular pharmacology.
[47] P. Timmermans,et al. Regional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists , 1991, Neuroscience Letters.
[48] J. Laragh. New angiotensin converting enzyme inhibitors. Their role in the management of hypertension. , 1990, American journal of hypertension.
[49] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.
[50] P. Timmermans,et al. Angiotensin II monoclonal antibody: blood pressure effects in normotensive and spontaneously hypertensive rats. , 1990, European journal of pharmacology.
[51] P. Timmermans,et al. Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. , 1990, Kidney international.
[52] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. , 1990, Trends in pharmacological sciences.
[53] P. Timmermans,et al. Nonpeptide Angiotensin II Receptor Antagonists: Studies With EXP9270 and DuP 753 , 1990, Hypertension.
[54] P. Timmermans,et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X. , 1990, Hypertension.
[55] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.
[56] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.
[57] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.
[58] P. Timmermans,et al. EXP 6803, A Nonpeptide Angiotensin II Receptor Antagonist , 1989 .
[59] P. Timmermans,et al. Identification of angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.
[60] B. Zimmerman. Monoclonal Antibodies and Nonpeptide Antagonists to Angiotensin II Potential Implications , 1989, Hypertension.
[61] J. Duncia,et al. Discrimination of angiotensin II receptor subtypes by dithiothreitol. , 1989, European journal of pharmacology.
[62] H. Baumgartner,et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.
[63] P. Timmermans,et al. Nonpeptide Angiotensin II Receptor Antagonists. IV. EXP6155 and EXP6803 , 1989, Hypertension.
[64] V. Dzau,et al. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.
[65] B. Berk,et al. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. , 1989, Hypertension.
[66] P. Timmermans,et al. Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308. , 1988, European journal of pharmacology.
[67] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307). , 1988, The Journal of pharmacology and experimental therapeutics.
[68] G. Lamas,et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.
[69] O. Paulson,et al. Role of angiotensin in autoregulation of cerebral blood flow , 1988, Circulation.
[70] R. Re,et al. New approaches to the study of the cellular biology of the cardiovascular system , 1988, Circulation.
[71] D. Ganten,et al. Intracardiac generation of angiotensin and its physiologic role , 1988, Circulation.
[72] Vicotor J Dzau,et al. Circulating versus local renin‐angiotensin system in cardiovascular homeostasis , 1988, Circulation.
[73] M. Peach,et al. Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells , 1988, Circulation research.
[74] D. Campbell,et al. Circulating and Tissue Angiotensin Systems , 1987 .
[75] B. Brenner,et al. Reversing glomerular hypertension stabilizes established glomerular injury. , 1987, Kidney international.
[76] P. Timmermans,et al. Monoclonal antibodies to angiotensin II. , 1987, Biochemical and biophysical research communications.
[77] S. Wood,et al. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. , 1987, British medical journal.
[78] J. Cutler,et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. , 1986, Progress in cardiovascular diseases.
[79] Semple Pf,et al. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. , 1986 .
[80] J. Rouleau,et al. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. , 1985, Circulation.
[81] Harrison Mj. Hypertension and stroke. , 1984, British journal of hospital medicine.
[82] B. Massie,et al. Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.
[83] J. Cohn,et al. Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.
[84] T. Ryan,et al. Angiotensin Converting Enzyme Inhibition in Patients with Congestive Heart Failure , 1978, Circulation.
[85] J. Cohn,et al. Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.
[86] M. Maxwell,et al. Pressor Response to Saralasin (1-Sar-8-Ala-Angiotensin II) Bolus Injection in Hypertensive Patients , 1978, Circulation.
[87] M. Peach. Renin-angiotensin system: biochemistry and mechanisms of action. , 1977, Physiological reviews.
[88] D. Streeten,et al. Pressor Response to 1‐Sar‐8‐Ala‐Angiotensin II (Saralasin) in Hypertensive Subjects , 1977, Circulation research.
[89] M. Peach,et al. Mechanism for the Positive Inotropic Effect of Angiotensin II on Isolated Cardiac Muscle , 1976, Circulation research.
[90] J. Laragh,et al. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients. , 1976, The American journal of medicine.
[91] H. Muller,et al. CONTRACTILE PROTEINS IN EXPERIMENTAL AND HUMAN NEOPLASIA , 1975, The Lancet.
[92] D. Streeten,et al. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. , 1975, The New England journal of medicine.
[93] J. Laragh,et al. Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. , 1973, Lancet.
[94] J. Laragh,et al. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. , 1972, The American journal of medicine.
[95] D. Pals,et al. A Specific Competitive Antagonist of the Vascular Action of Angiotensin II , 1971, Circulation research.
[96] D. C. Fessler,et al. Role of the Pressor Action of Angiotensin IIin Experimental Hypertension , 1971, Circulation research.
[97] M. Worcel,et al. The Role of Angiotensin: Indirect Studies with Antiangiotensin Plasma , 1970, Circulation research.
[98] B. Waeber,et al. Angiotensin-converting enzyme inhibitors in hypertension , 1995 .
[99] P. Timmermans,et al. In vivo pharmacology of DuP 753. , 1991, American journal of hypertension.
[100] J. Laragh. Renin system blockade as a therapeutic strategy. Past, present, and future. , 1991, American journal of hypertension.
[101] R. Kauffman,et al. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. , 1991, Life sciences.
[102] S. Gardiner,et al. Differential regional haemodynamic effects of the non-peptide angiotensin II antagonist, DuP 753, in water-replete and water-deprived Brattleboro rats. , 1991, Life sciences.
[103] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents. , 1990, Blood vessels.
[104] S. Whitebread,et al. Biochemical characterization of two angiotensin II receptor subtypes in the rat. , 1990, Journal of cardiovascular pharmacology.
[105] E. Ritz,et al. Detrimental and beneficial effects of converting enzyme inhibitors on the kidney. , 1990, Journal of cardiovascular pharmacology.
[106] S. Whitebread,et al. Binding characteristics and vascular effects of various angiotensin II antagonists. , 1990, Journal of cardiovascular pharmacology.
[107] H. Baumgartner,et al. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. , 1990, Journal of cardiovascular pharmacology.
[108] M. Peach,et al. The angiotensin II receptor and the actions of angiotensin II. , 1990, Journal of cardiovascular pharmacology.
[109] T. Resink,et al. Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. , 1990, Journal of cardiovascular pharmacology.
[110] S. Anderson. Renal Effects of Converting Enzyme Inhibitors in Hypertension and Diabetes , 1990, Journal of cardiovascular pharmacology.
[111] Tissue renin-angiotensin system: physiologic and pharmacologic implications. New York, New York, May 17, 1987. Proceedings. , 1988, Circulation.
[112] W. Price,et al. Characterization of the functional antagonism and antihypertensive activity displayed by a monoclonal antibody to angiotensin II. , 1988, The Journal of pharmacology and experimental therapeutics.
[113] B. Waeber,et al. Renal Effects of Converting Enzyme Inhibition , 1987, Journal of cardiovascular pharmacology.
[114] Phillips Mi. Functions of Angiotensin in the Central Nervous System , 1987 .
[115] P. Semple,et al. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. , 1986, The New England journal of medicine.